Trials
Search / Trial NCT00002450

Safety and Effectiveness of Tenofovir Disoproxil Fumarate (Tenofovir DF) Plus Other Anti-HIV Drugs in HIV-Infected Patients

Launched by GILEAD SCIENCES · Aug 30, 2001

Trial Information

Current as of March 16, 2025

Completed

Keywords

Hiv 1 Drug Therapy, Combination Drug Administration Schedule Rna, Viral Anti Hiv Agents Viral Load

ClinConnect Summary

Patients are randomized 2:1 to add tenofovir DF once daily or placebo to their existing antiretroviral regimen in a blinded manner. Patients are stratified according to HIV-1 RNA level, CD4 cell count, and number of antiretroviral drugs taken prior to study entry. Patients and physicians are strongly discouraged from making changes in their antiviral therapies for at least 24 weeks post-randomization. After Week 24, changes in background antiretroviral therapy are permitted. At 24 weeks post-randomization, patients randomized to receive placebo are crossed over to receive open-label tenofov...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Patients may be eligible for this study if they:
  • Are HIV-positive.
  • Have been on stable anti-HIV therapy for at least 8 weeks with no more than 4 anti-HIV drugs at the time of study entry.
  • Have a viral load (level of HIV in the blood) between 400 and 10,000 copies/ml.
  • Have good kidney function.
  • Are 18 to 65 years old.
  • Agree to use a barrier method of birth control (such as condoms) during the study and for 30 days after.
  • Exclusion Criteria
  • Patients will not be eligible for this study if they:
  • Have a new AIDS-related illness diagnosed within 30 days of study entry.
  • Have any other serious medical conditions, including kidney or bone disease, an active infection requiring antibiotics, or cancer (other than Kaposi's sarcoma or certain skin cancers).
  • Have received a vaccine within 30 days of study entry.
  • Are unable to take medications by mouth.
  • Have ever taken tenofovir or adefovir dipivoxil.
  • Have taken certain medications within 30 days of study entry, such as chemotherapy, corticosteroids, medications that affect the kidneys, treatment for Kaposi's sarcoma, or certain experimental drugs.
  • Abuse alcohol or drugs.
  • Are pregnant or breast-feeding.

About Gilead Sciences

Gilead Sciences is a leading biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines to address unmet medical needs. With a strong emphasis on antiviral therapies, particularly for HIV, hepatitis B, hepatitis C, and influenza, Gilead leverages advanced research and development capabilities to drive breakthroughs in treatment and care. The company is committed to improving patient outcomes through rigorous clinical trials, fostering collaborations with healthcare professionals, and engaging in partnerships to enhance global health. Gilead's dedication to scientific excellence and patient-centric approaches positions it at the forefront of the biopharmaceutical industry.

Locations

Miami, Florida, United States

Birmingham, Alabama, United States

Bronx, New York, United States

Rochester, New York, United States

Washington, District Of Columbia, United States

Boston, Massachusetts, United States

Los Angeles, California, United States

Providence, Rhode Island, United States

Detroit, Michigan, United States

Los Angeles, California, United States

Ponce, , Puerto Rico

Dallas, Texas, United States

San Antonio, Texas, United States

Boston, Massachusetts, United States

New York, New York, United States

Hampton, Virginia, United States

San Diego, California, United States

San Francisco, California, United States

Hershey, Pennsylvania, United States

Phoenix, Arizona, United States

Vero Beach, Florida, United States

Santurce, , Puerto Rico

Los Angeles, California, United States

Annandale, Virginia, United States

Los Angeles, California, United States

Oakland, California, United States

Columbus, Ohio, United States

Houston, Texas, United States

Denver, Colorado, United States

Albany, New York, United States

San Francisco, California, United States

Tampa, Florida, United States

Tacoma, Washington, United States

Chicago, Illinois, United States

Miami, Florida, United States

New York, New York, United States

Oklahoma City, Oklahoma, United States

Fort Lauderdale, Florida, United States

Atlanta, Georgia, United States

Brooklyn, New York, United States

San Juan, , Puerto Rico

Torrance, California, United States

New Haven, Connecticut, United States

Charlotte, North Carolina, United States

Atlanta, Georgia, United States

Houston, Texas, United States

San Francisco, California, United States

Long Beach, California, United States

Washington, District Of Columbia, United States

Long Beach, California, United States

Dallas, Texas, United States

Los Angeles, California, United States

New Haven, Connecticut, United States

Fort Pierce, Florida, United States

Lafayette, Louisiana, United States

Baltimore, Maryland, United States

St. Paul, Minnesota, United States

Albuquerque, New Mexico, United States

New York, New York, United States

Columbus, Ohio, United States

Puyallup, Washington, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials